-
Taxonomy & unit
-
us-gaap: CAD/shares and USD/shares
-
Description
-
The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
-
Summary
-
Amicus Therapeutics, Inc. quarterly Earnings Per Share, Diluted history and growth rate from Q1 2021 to Q3 2022.
- Amicus Therapeutics, Inc. Earnings Per Share, Diluted for the quarter ending September 30, 2022 was -0.12 CAD/shares, a 36.8% increase year-over-year.
Earnings Per Share, Diluted, Quarterly (CAD/shares)
Earnings Per Share, Diluted, YoY Quarterly Growth (%)